Has BioRad Laboratories (BIO) Outpaced Other Medical Stocks This Year?

Company Overview - Bio-Rad Laboratories (BIO) is part of the Medical sector, which includes 1013 individual stocks and currently holds a Zacks Sector Rank of 4 [2] - The Zacks Rank for Bio-Rad Laboratories is 2 (Buy), indicating a positive outlook based on earnings estimates and revisions [3] Performance Metrics - The Zacks Consensus Estimate for Bio-Rad's full-year earnings has increased by 0.7% over the past quarter, reflecting stronger analyst sentiment and an improving earnings outlook [4] - Year-to-date, Bio-Rad has gained approximately 7.5%, outperforming the average return of 5.7% for Medical companies [4] - In the Medical - Products industry, which includes 83 stocks, Bio-Rad is ranked 140 and has slightly underperformed its industry, which has gained an average of 9.8% this year [6] Comparative Analysis - Certara, Inc. (CERT) is another Medical stock that has outperformed the sector with a year-to-date return of 31.3% and a Zacks Rank of 2 (Buy) [5] - Certara belongs to the Medical - Biomedical and Genetics industry, which is ranked 68 and has increased by 4.5% this year [6] Investment Outlook - Both Bio-Rad Laboratories and Certara, Inc. are highlighted as stocks to watch for investors interested in the Medical sector due to their solid performance [7]